Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 8:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 6,433 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin to Skin Clear all
Completed Not applicable Interventional Results available

Dietary Salt in Rheumatoid Arthritis

NCT03649178
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
salt
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 21, 2026, 8:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate the Whitening Effect of Mineral Sunscreens in Multi-Cultural Skin Tones

NCT05565625
View directory record Official record
Conditions
Sunscreen
Interventions
Sunscreen A, Sunscreen B, Sunscreen C, Sunscreen D, Sunscreen E, Sunscreen F
Other
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Oct 21, 2026, 8:34 PM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%

NCT00599521
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene lotion 0.1%, Adapalene Lotion Vehicle
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
1,067 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
29
States / cities
San Diego, California • Vista, California • Denver, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 21, 2026, 8:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Randomized Controlled Trial to Evaluate the Safety and Efficacy of an Oral Supplement in Supporting Vision and Eye Health

NCT07123584
View directory record Official record
Conditions
Dry Eye, Eye Fatigue
Interventions
Eye Empower, Placebo
Dietary Supplement
Lead sponsor
Bio Nature Health
Industry
Eligibility
45 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 21, 2026, 8:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE Vaccine

NCT01751048
View directory record Official record
Conditions
Leishmaniasis
Interventions
GLA-SE, LEISH-F3, MPL-SE, SE
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 2, 2017 · Synced Oct 21, 2026, 8:34 PM EDT
Completed Phase 3 Interventional Results available

StrataGraft® Skin Tissue in the Promotion of Autologous Skin Regeneration of Complex Skin Defects Due to Thermal Burns That Contain Intact Dermal Elements

NCT03005106
View directory record Official record
Conditions
Burn, Thermal
Interventions
StrataGraft Skin Tissue, Autograft
Biological · Procedure
Lead sponsor
Stratatech, a Mallinckrodt Company
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
16
States / cities
Mobile, Alabama • Phoenix, Arizona • Orange, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Oct 21, 2026, 8:34 PM EDT
Terminated No phase listed Observational

Blood Samples From Patients on a Clinical Trial to CINV During HSCT

NCT00900068
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nausea and Vomiting, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
immunoenzyme technique, laboratory biomarker analysis, medical chart review
Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 21, 2026, 8:34 PM EDT
Completed Phase 4 Interventional Results available

Vascular Inflammation in Psoriasis Trial (The VIP Trial)

NCT01553058
View directory record Official record
Conditions
Psoriasis, Cardiovascular Disease
Interventions
Adalimumab (Humira), Placebo Injection, NB-UVB phototherapy
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
9
States / cities
Sacramento, California • Denver, Colorado • Bethesda, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Oct 21, 2026, 8:34 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

NCT05976243
View directory record Official record
Conditions
Chronic Inducible Urticaria
Interventions
Remibrutinib, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
25
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 21, 2026, 8:34 PM EDT
Completed Phase 1Phase 2 Interventional

A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma

NCT00304525
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
RAF265
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
10
States / cities
Aurora, Colorado • Augusta, Georgia • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 21, 2026, 8:34 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome

NCT00465985
View directory record Official record
Conditions
Muckle Wells Syndrome
Interventions
ACZ885, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
4 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 28, 2017 · Synced Oct 21, 2026, 8:34 PM EDT
Completed Phase 4 Interventional Results available

Adherence to Study Medication Compared to Generic Topical Clindamycin Plus Generic Topical Tretinoin in Subjects With Mild to Moderate Acne Vulgaris

NCT01047189
View directory record Official record
Conditions
Acne Vulgaris
Interventions
clindamycin phosphate 1.2% and tretinoin 0.025%, clindamycin 1% gel, tretinoin 0.025% cream
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
12 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 21, 2026, 8:34 PM EDT
Terminated Phase 3 Interventional Results available

Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss

NCT04251533
View directory record Official record
Conditions
Triple Negative Breast Neoplasms
Interventions
alpelisib, placebo, nab-paclitaxel
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
5
States / cities
Los Angeles, California • Baton Rouge, Louisiana • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 21, 2026, 8:34 PM EDT
Terminated No phase listed Observational

Natural History Study to Characterise the Course of Disease Progression in Participants With Mucopolysaccharidosis Type IIIB

NCT02293408
View directory record Official record
Conditions
MPS IIIB (Sanfilippo B Syndrome)
Interventions
Not listed
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
1 Year and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Minneapolis, Minnesota • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Oct 21, 2026, 8:34 PM EDT
Completed Not applicable Interventional Results available

A Soft Silicone Wound Contact Layer Containing Silver in the Treatment of Skin Grafts in Surgical Burn Patients.

NCT02210208
View directory record Official record
Conditions
Burn Injury, Skin Graft
Interventions
Mepitel® Ag, Mepilex® Transfer Ag
Device
Lead sponsor
Molnlycke Health Care AB
Industry
Eligibility
18 Months to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Phoenix, Arizona • Orlando, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2018 · Synced Oct 21, 2026, 8:34 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Fixed Combination Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris

NCT00441415
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene BPO
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years to 35 Years
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
4
States / cities
Santa Monica, California • Fridley, Minnesota • Albuquerque, New Mexico + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Oct 21, 2026, 8:34 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Ceftaroline Versus Linezolid in Subjects With Complicated Skin and Skin Structure Infections

NCT00633152
View directory record Official record
Conditions
Bacterial Infection
Interventions
ceftaroline, linezolid, Aztreonam
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
13
States / cities
Buena Park, California • Long Beach, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 21, 2026, 8:34 PM EDT
Completed Phase 1 Interventional

A Study of LY3361237 in Participants With Systemic Lupus Erythematosus

NCT03933943
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
LY3361237, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Anniston, Alabama • Clearwater, Florida • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Oct 21, 2026, 8:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Study of Linerixibat in Adults With Moderate Hepatic Impairment and Healthy Controls

NCT05393076
View directory record Official record
Conditions
Pruritus
Interventions
Linerixibat
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Oct 21, 2026, 8:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Pomegranate on Aging and Inflammation of the Skin

NCT02258776
View directory record Official record
Conditions
Skin Photoaging, Inflammation and Skin Pathogenic Bacteria
Interventions
Pomegranate Extract, Pomegranate Juice, Placebo
Dietary Supplement
Lead sponsor
University of California, Los Angeles
Other
Eligibility
30 Years to 45 Years · Female only
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 21, 2026, 8:34 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Twelve Week Safety and Efficacy Study in Rosacea

NCT01784133
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
omiganan, placebo
Drug
Lead sponsor
Maruho Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
17
States / cities
Birmingham, Alabama • Santa Monica, California • New Haven, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Oct 21, 2026, 8:34 PM EDT
Completed Phase 2 Interventional

Molecular Marker Profiling of Axillary Lymph Nodes in Predicting Response in Patients With Locally Advanced or Metastatic Breast Cancer Who Are Undergoing Chemotherapy Followed By Surgery

NCT00233974
View directory record Official record
Conditions
Breast Cancer
Interventions
PET (positron emission tomography)
Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 7, 2012 · Synced Oct 21, 2026, 8:34 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer

NCT02091960
View directory record Official record
Conditions
HER2 Amplified, Advanced Breast Cancer, Human Epidermal Growth Factor Receptor 2 (HER2)
Interventions
Enzalutamide, Trastuzumab
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
16
States / cities
Anaheim, California • Los Angeles, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 21, 2026, 8:34 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis

NCT05730725
View directory record Official record
Conditions
Psoriasis
Interventions
BMS-986322, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
19
States / cities
Birmingham, Alabama • Encino, California • Fountain Valley, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 21, 2026, 8:34 PM EDT